first look even ew immun ew
expect flattish tavr sale year
edward report result even sale came consensu estim unlik compani edward
provid best take outlook provid updat guidanc ew expect full year underli sale growth flattish
versu prior guidanc continu rate ew underweight
gener theme thing track well earli quarter even littl ahead edward expect
impact hit mid-march
manag note transcathet aortic valv replac tavr sale growth track consist global growth rate
last week quarter tavr procedur dramat impact decreas result
look ahead manag expect see greatest impact expect see improv
see better resembl compani origin expect guidanc assum second wave updat
underli revenu guidanc
tavr sale ore flattish year manag still maintain longer term outlook tavr
transcathet mitral tricuspid tmtt sale year prior
critic sale flattish prior
confer call on-going see detail quarter maintain underweight rate continu believ
stock overvalu
oo look bloomberg im reach question detail kstew
sale ep
sale ere billion bloomberg billion streetaccount billion ere in-lin ith estim
billion result ere edw ardss guidanc usual sale grow th driven
perform tavr busi
adjust ep ere also bloomberg streetaccount barclay ep ere ithin albeit
low er end edw ardss guidanc edw ard repurchas million share
tavr sale ere million hich ere streetaccount consensu estim million estim
underli tavr sale growth manag comment sale grow th consist ith global
grow th rate last eek quarter tavr procedur ere dramat impact decreas result
also note averag sell price ere stabl also note averag sell price ere stabl
transcathet mitral tricuspid therapi
in-lin consensu million estim million manag note
 experienc strong momentum acceler adopt pascal europ ever sale last eek declin
abruptli due
manag comment ill updat pascal cardioband evoqu tricuspid replac system
europcr medic meet unclear hen meet ill held pari due franc limit larg public gather
surgic structur heart sale ere million consensu million ere dow underli basi
manag cite continu headw ind ow ing tavr adopt us partial off-set continu adopt inspiri
surgic aortic valv manag also note sharp deceler last eek march result
critic sale ere million consensu million ere underli basi manag
note perform lift strong demand compani dispos pressur monitor devic use icu due
pandem
edw ard turn impress ep beat ith adjust ep rel consensu ithin pre-pandem
guidanc rang rel expect beat mainli function gross margin ere higher
expect hile sg ere low er expect
guidanc updat lower sale ep expect owe
full year given on-going impact edw ard low ere guidanc expect sale billion versu
prior billion bracket consensu billion manag also low ere ep guidanc versu
prior also bracket consensu expect impact sale expect sever
follow ed gradual recoveri better resembl compani origin expect
manag expect sale million street million impli declin compani
provid ep guidanc rang
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog believ
multipl ew share ill like compress given potenti slow er grow th believ ill harder increment
penetr tavr market tmtt opportun ill like take longer play price target appli price-to-earnings
multipl ep estim
risk may imped achiev barclay research valuat price greater transcathet aortic
valv replac tavr sale success transcathet mitral tricuspid therapi tmtt could result higher earn
chang reimburs product failur valv thrombosi advers long-term outcom hich may chang usag
trend product patent litig outcom fda govern action
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
